SGRY · Surgery Partners, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $102.3M | first quarter | — |
|
|
|||
| Borrowing capacity under revolving credit facility | $666.1M | as of March 31, 2026 | — |
| Revenue per case growth | 3.8% | first quarter | — |
|
|
|||
| Same-facility cases growth | 0.6% | first quarter | — |
|
|
|||
| Same-facility revenues growth | 4.4% | first quarter | — |
|
|
|||
| Total net debt to EBITDA ratio non-GAAP | 4.3 | end of the first quarter | — |
|
|
|||
| Leverage calculated using consolidated debt from balance sheet divided by Adjusted EBITDA, befor non-GAAP | 4.9 | the fourth quarter | — |
| Surgical cases | -2.1% | the fourth quarter | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SGRY
this stock
Surgery Partners, Inc.
|
$2.08B | +6.2% | +41.7% | — | 11.3% |
|
HCA
HCA Healthcare, Inc.
|
$90.55B | -12.4% | +7.1% | 14.1 | 2.6% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.38B | -10.8% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.35B | +29.6% | -2.3% | 9.8 | 3.7% |
|
DVA
Davita Inc.
|
$15.33B | +112.1% | +6.5% | 22.3 | 7.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SGRY | +8.3% | -2.3% | +16.8% | -2.3% | +6.2% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | +10.7% | +0.0% | +10.5% | +0.0% | -0.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.